Two new entrants into the PI3 kinase (PI3K) inhibitor space presented at the American Society of Hematology annual meeting may help reinvigorate a class of drugs for indolent non-Hodgkin’s lymphomas (NHL) whose members have often had to contend with unfavorable toxicity profiles. The two drugs – TG Therapeutics, Inc.’ umbralisib and Incyte Corporation’s parsaclisib – have shown high response rates and significantly better safety and tolerability than two of the PI3K inhibitors on the market, Gilead Sciences, Inc.’ Zydelig (idelalisib) and Verastem, Inc.’s Copiktra (duvelisib).
On 7 December, TG presented data from the Phase IIb UNITY-NHL study in marginal zone lymphoma (MZL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL), while Incyte presented data from the
